New York, Nov. 19, 2024 Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a pioneering biotechnology company focused on developing transformative immunomodulation therapies, announced a significant milestone in their journey towards combating Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig s disease. The ALS Association has approved Tiziana’s grant application under the prestigious Hoffman ALS Clinical Trial Awards Program, earmarking funding for a groundbreaking clinical trial involving the company s lead development candidate, intranasal foralumab.
Understanding the Grant and Clinical Trial s
The grant from the ALS Association will facilitate a 20-patient clinical trial aimed at assessing the safety and early-stage efficacy of intranasal foralumab, a fully human, anti-CD3 monoclonal antibody. Intranasal administration offers potential advantages by allowing the therapeutic agent to directly target the central nervous system while minimizing systemic exposure and related side effects.
The trial
Comments